Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

FDA Gives Go-Ahead to New Medtronic Stent

By Drug Discovery Trends Editor | September 21, 2010

MINNEAPOLIS (AP) – Medtronic Inc., the world’s largest medical device maker, said it has received U.S. approval for a new artery-bracing stent that may be easier for surgeons to implant.

The Food and Drug Administration approved the company’s Integrity bare metal stent, which features a new, more flexible construction.

Stents are mesh-metal tubes designed to hold arteries open after they have been cleared of potentially deadly plaque. The devices are usually threaded into a small incision in the groin and then up into the patient’s artery. Once the catheter reaches the blockage, a balloon inflates, crushing the plaque and squeezing the stent into place.

Medtronic said its new stent differs from older models because it is made from one continuous piece of metal. The company’s previous metal stent, Driver, was made from a series of rings fused together.

Medtronic markets both bare metal and drug-coated stents. The drug coatings are designed to prevent scar tissue from growing back through the mesh and reclogging the patient’s artery.

A company spokesman said the approval of Integrity will allow Medtronic to explore drug-filled stent technology, versus currently available drug-coated stents. Some research suggests the polymers used to coat stents with drugs can lead to blood clots.

Date: September 20, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE